Department of Pediatrics, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea.
J Korean Med Sci. 2024 Feb 26;39(7):e64. doi: 10.3346/jkms.2024.39.e64.
The treatment of pediatric patients with latent tuberculosis infection (LTBI) is a crucial TB control strategy. LTBI is not a reportable communicable disease, and data regarding LTBI treatment in pediatric patients in Korea are scarce. This study aimed to investigate the prescription patterns and treatment completion rates among pediatric patients with LTBI in Korea by analyzing National Health reimbursement claims data.
We retrospectively analyzed outpatient prescription records for pediatric patients aged 18 or younger with LTBI-related diagnostic codes from 2016 to 2020. We compared the frequency of prescriptions for the standard treatment regimen (9 months of isoniazid [9H]) and an alternative treatment regimen (3 months of isoniazid plus rifampicin [3HR]). We also assessed the treatment incompletion rates by age group, treatment regimen, treatment duration, the level of medical facility, physician's specialty, and hospital location. We performed multivariable analysis to identify factors influencing treatment incompletion.
Among the 11,362 patients who received LTBI treatment, 6,463 (56.9%) were prescribed the 9H regimen, while 4,899 (43.1%) received the 3HR regimen. Patients in the 3HR group were generally older than those in the 9H group. The proportion of 3HR regimen prescriptions significantly greater in the later period (2018-2020), in primary hospitals, under the management of non-pediatric specialists, and in metropolitan regions. The overall treatment incompletion rate was 39.7% (9H group: 46.9%, 3HR group: 30.3%). In the multivariable analysis, 9H regimen prescription was the strongest factor associated with treatment incompletion (adjusted odds ratio, 2.42; 95% confidence interval, 2.20-2.66; < 0.001). Additionally, management in a primary hospital, a hospital's location in a non-metropolitan region, and management by a non-pediatric specialist were also significant risk factors for treatment incompletion.
Our study results suggest that promoting the use of 3HR regimen prescriptions could be an effective strategy to enhance treatment completion. Physicians in primary hospitals, hospitals located in non-metropolitan regions, and physicians without a pediatric specialty require increased attention when administering LTBI treatment to pediatric patients to ensure treatment completion.
儿童潜伏性结核感染(LTBI)的治疗是结核病控制的重要策略。LTBI 不是法定传染病,韩国关于儿科 LTBI 治疗的数据很少。本研究旨在通过分析国家健康报销索赔数据,调查韩国儿科 LTBI 患者的处方模式和治疗完成率。
我们回顾性分析了 2016 年至 2020 年有 LTBI 相关诊断代码的 18 岁以下门诊处方记录。我们比较了标准治疗方案(9 个月异烟肼[9H])和替代治疗方案(3 个月异烟肼加利福平[3HR])的处方频率。我们还按年龄组、治疗方案、治疗持续时间、医疗机构级别、医生专业和医院所在地评估了治疗不完成率。我们进行了多变量分析,以确定影响治疗不完成的因素。
在接受 LTBI 治疗的 11362 名患者中,6463 名(56.9%)接受了 9H 方案治疗,4899 名(43.1%)接受了 3HR 方案治疗。3HR 组患者普遍比 9H 组患者年龄大。在后期(2018-2020 年)、初级医院、非儿科专家管理和大都市地区,3HR 方案的处方比例显著增加。总体治疗不完成率为 39.7%(9H 组:46.9%,3HR 组:30.3%)。多变量分析显示,9H 方案处方是治疗不完成的最强相关因素(调整优势比,2.42;95%置信区间,2.20-2.66;<0.001)。此外,在初级医院管理、非大都市地区医院位置和非儿科专家管理也是治疗不完成的显著危险因素。
我们的研究结果表明,推广使用 3HR 方案处方可能是提高治疗完成率的有效策略。初级医院的医生、非大都市地区的医院和没有儿科专业的医生在为儿科患者进行 LTBI 治疗时需要更加注意,以确保治疗完成。